https://scholars.lib.ntu.edu.tw/handle/123456789/604890
標題: | Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer | 作者: | Lin, Yu-Lin JAU-YU LIAU SHAN-CHI YU LI-HUI TSENG LIANG-IN LIN JIN-TUNG LIANG BEEN-REN LIN JI-SHIANG HUNG YIH-LEONG CHANG KUN-HUEI YEH ANN-LII CHENG |
關鍵字: | DNA-DAMAGE RESPONSE; 1ST-LINE TREATMENT; CETUXIMAB; MUTATIONS; FLUOROURACIL; LEUCOVORIN | 公開日期: | 六月-2013 | 出版社: | NEOPLASIA PRESS | 卷: | 6 | 期: | 3 | 起(迄)頁: | 363 | 來源出版物: | Translational oncology | 摘要: | The identification of better regimens in currently available chemotherapeutic agents is crucial for treating patients with KRAS mutant metastatic colorectal cancer (mCRC). Records of mCRC patients who received first-line oxaliplatin-based or irinotecan-based regimens were reviewed retrospectively. Clinicopathologic features and treatment outcome of patients with first-line progression-free survival (PFS) and overall survival (OS) in association with KRAS mutation status were analyzed using the Cox proportional hazard model. Between 2007 and 2010, a total of 118 mCRC patients were enrolled. Among them, 67 were males and 51 were females. In patients who received first-line oxaliplatin-based regimens, the PFS was significantly longer in KRAS mutant patients (N = 32) than that in KRAS wild-type patients (N = 51). The median PFS was 8.5 months in KRAS mutant versus 5.8 months in KRAS wild-type patients (P = .008). In contrast, in patients who received first-line irinotecan-based regimens, the PFS was shorter in KRAS mutant patients (N = 15) than that in KRAS wild-type patients (N = 20). Median PFS was 3.9 months in KRAS mutant versus 6.0 months in KRAS wild-type patients (P = .23). Median OS between KRAS mutant and wild-type patients was not significantly different in both oxaliplatin-based and irinotecan-based regimens. In multivariate analyses, KRAS mutation remains an independent predictive factor for longer PFS in first-line oxaliplatin-based regimens. In conclusion, oxaliplatin-based chemotherapy in KRAS mutant mCRC might result in longer PFS than in KRAS wild-type mCRC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/604890 | ISSN: | 1936-5233 | DOI: | 10.1593/tlo.13166 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。